Evidence for an autoimmune pathogenesis of vitiligo
- PMID: 12622785
- DOI: 10.1034/j.1600-0749.2003.00023.x
Evidence for an autoimmune pathogenesis of vitiligo
Abstract
Vitiligo is a depigmenting disorder characterized by the development of white patches in various distributions, which are due to the loss of melanocytes from the epidermis. A variety of arguments from clinical observations to research findings in human and animal models support the hypothesis of autoimmunity and are reviewed in this article. The association with autoimmune diseases and organ-specific autoantibodies is well known. Various effective treatment options have an immunosuppressive effect. Today the autoimmune pathogenesis of the disease has become a rapidly evolving field of research. Detection of circulating melanocyte antibodies in human and animal models implicates a possible role of humoral immunity. Histological and immunohistochemical studies in perilesional skin suggest the involvement of cellular immunity in vitiligo. Recently, T-cell analyses in peripheral blood further support this hypothesis. Interestingly, new insights in the association of vitiligo and melanoma may help to clarify the role of autoimmunity in the development of vitiligo.
Similar articles
-
Autoimmune aspects of vitiligo.Autoimmunity. 2001;34(1):65-77. doi: 10.3109/08916930108994127. Autoimmunity. 2001. PMID: 11681494 Review.
-
Physiopathology and genetics of vitiligo.J Autoimmun. 2005;25 Suppl:63-8. doi: 10.1016/j.jaut.2005.10.001. Epub 2005 Nov 18. J Autoimmun. 2005. PMID: 16298511 Review.
-
Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?Pigment Cell Res. 2005 Aug;18(4):234-42. doi: 10.1111/j.1600-0749.2005.00244.x. Pigment Cell Res. 2005. PMID: 16029417 Review.
-
Immunopathogenesis of vitiligo.Autoimmun Rev. 2011 Oct;10(12):762-5. doi: 10.1016/j.autrev.2011.02.004. Epub 2011 Feb 18. Autoimmun Rev. 2011. PMID: 21334464 Review.
-
Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo.Autoimmun Rev. 2007 Jan;6(3):138-42. doi: 10.1016/j.autrev.2006.09.010. Epub 2006 Oct 2. Autoimmun Rev. 2007. PMID: 17289548 Review.
Cited by
-
Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis.Syst Rev. 2024 Oct 2;13(1):250. doi: 10.1186/s13643-024-02653-7. Syst Rev. 2024. PMID: 39358803 Free PMC article.
-
Topical application of simvastatin acid sodium salt and atorvastatin calcium salt in vitiligo patients. Results of the randomized, double-blind EVRAAS pilot study.Sci Rep. 2024 Jun 25;14(1):14612. doi: 10.1038/s41598-024-65722-w. Sci Rep. 2024. PMID: 38918590 Free PMC article. Clinical Trial.
-
Vitiligo Treated with Combined Piperine-Based Topical Treatment and Narrowband Ultraviolet B Therapy: Follow-Up with Reflectance Confocal Microscopy.Diagnostics (Basel). 2024 Feb 25;14(5):494. doi: 10.3390/diagnostics14050494. Diagnostics (Basel). 2024. PMID: 38472966 Free PMC article.
-
The effect of antioxidant dietary supplements and diet-derived circulating antioxidants on vitiligo outcome: evidence from genetic association and comprehensive Mendelian randomization.Front Nutr. 2024 Jan 11;10:1280162. doi: 10.3389/fnut.2023.1280162. eCollection 2023. Front Nutr. 2024. PMID: 38274214 Free PMC article.
-
Desnutrin as a Biomarker for Insulin Resistance in Patients with Vitiligo Vulgaris.Indian J Dermatol. 2023 Jul-Aug;68(4):366-371. doi: 10.4103/ijd.ijd_435_22. Indian J Dermatol. 2023. PMID: 37822413 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
